Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target hoisted by Mizuho from $144.00 to $150.00 in a report published on Tuesday. The brokerage currently has a neutral rating on the specialty pharmaceutical company’s stock.

A number of other research firms have also recently weighed in on JAZZ. FBR & Co initiated coverage on Jazz Pharmaceuticals in a report on Thursday, October 19th. They issued a buy rating and a $206.00 price target for the company. Wells Fargo & Company reaffirmed an outperform rating and issued a $177.00 price target (down previously from $178.00) on shares of Jazz Pharmaceuticals in a report on Thursday, August 10th. Royal Bank Of Canada reduced their target price on Jazz Pharmaceuticals from $210.00 to $195.00 and set an outperform rating for the company in a report on Wednesday, November 8th. Cantor Fitzgerald reissued a buy rating on shares of Jazz Pharmaceuticals in a report on Tuesday, August 29th. Finally, Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a report on Thursday, September 28th. They set a neutral rating and a $165.00 target price for the company. Two analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $181.28.

Jazz Pharmaceuticals (NASDAQ JAZZ) traded down $0.81 during midday trading on Tuesday, reaching $135.75. The company had a trading volume of 451,300 shares, compared to its average volume of 508,983. The firm has a market cap of $8,186.84, a PE ratio of 17.13, a price-to-earnings-growth ratio of 0.88 and a beta of 0.98. Jazz Pharmaceuticals has a 12 month low of $99.28 and a 12 month high of $163.75. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63.

In related news, Director Patrick G. Enright sold 352 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the completion of the transaction, the director now directly owns 1,365 shares in the company, valued at $181,804.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $150.00, for a total value of $150,000.00. The disclosure for this sale can be found here. Insiders sold 10,352 shares of company stock valued at $1,417,763 over the last quarter. 4.30% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Toronto Dominion Bank boosted its position in shares of Jazz Pharmaceuticals by 12.4% during the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 81 shares during the period. US Bancorp DE boosted its position in shares of Jazz Pharmaceuticals by 94.4% during the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 368 shares during the period. Gargoyle Investment Advisor L.L.C. purchased a new position in shares of Jazz Pharmaceuticals during the second quarter worth $206,000. Advisor Group Inc. boosted its position in shares of Jazz Pharmaceuticals by 62.4% during the third quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock worth $210,000 after buying an additional 550 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Jazz Pharmaceuticals during the second quarter worth $211,000. Institutional investors and hedge funds own 91.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Jazz Pharmaceuticals (JAZZ) Given New $150.00 Price Target at Mizuho” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://theolympiareport.com/2017/12/06/jazz-pharmaceuticals-jazz-given-new-150-00-price-target-at-mizuho.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.